Autologous attenuated T-cell vaccine (Tovaxin) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies. Loftus B, Newsom B, Montgomery M, Von Gynz-Rekowski K, Riser M, Inman S, Garces P, Rill D, Zhang J, Williams JC Clin Immunol. 2009 May; 131(2):202-15. Epub 2009 Feb 18. PMID: 19230777. Abstract CommentRecommendBookmarkWatch